Pfizer → Wyeth
Pfizer's $68bn cash-and-stock takeover of Wyeth, agreed in January 2009, made it the world's largest pharmaceutical company and bought it vaccines, biologics, nutrition and consumer brands — most of which, apart from the medicines and vaccines, Pfizer sold or spun off within a decade.
A cash-and-stock deal financed partly with $22.5bn of bank debt raised during the financial crisis.
- Value
- $68B
- Announced
- January 2009
- Completed
- October 2009
- Sector
- Pharma
- Deal type
- acquisition
- Acquirer
- Pfizer (United States)
- Target
- Wyeth (United States)
Why it mattered
Pfizer faced the 2011 patent expiry of Lipitor, the best-selling drug ever, and Wyeth offered breadth: Prevnar, the world's largest-selling vaccine; Enbrel, the leading biologic, co-marketed with Amgen; Premarin and Effexor; nutritionals; and over-the-counter brands such as Advil. The two had met before — in 2000 Pfizer's hostile bid took Warner-Lambert away from Wyeth, then American Home Products, which had to settle for a $1.8bn payment.
The terms announced on 26 January 2009 gave Wyeth shareholders $33 in cash and 0.985 of a Pfizer share for each share, worth $50.19, or about $68bn in all. Pfizer promised about $4bn of cost savings by the third year, said no drug would account for more than 10% of the combined revenue in 2012, and, in connection with the deal, cut its quarterly dividend to $0.16 a share.
The obstacle was in animals rather than people. On 14 October 2009 the Federal Trade Commission settled its investigation by requiring Pfizer to sell about half of Wyeth's Fort Dodge animal health business in the United States, plus Pfizer's own horse vaccines, to Boehringer Ingelheim. The deal completed the next day, 15 October.
What it left behind
The lasting prize was the pneumococcal vaccine. Pfizer introduced the 13-strain Prevnar 13 in 2010, and the Prevnar family still grew 8% operationally in 2025. Much of the rest was sold. The nutrition business went to Nestlé for $11.85bn in cash in November 2012 and now trades as Wyeth Nutrition; the animal health business was floated as Zoetis in February 2013 and fully spun off that year; and the consumer brands went into a joint venture with GSK in 2019, 32% owned by Pfizer, that became Haleon. Pfizer also inherited Wyeth's liabilities, including $491m of penalties by 2014 over the marketing of Rapamune. Breadth bought to soften a patent cliff tends to survive only where it fits the buyer's core: within a decade Pfizer had turned Wyeth's non-prescription businesses back into cash and shares, and kept the vaccine franchise.